The aim of this project is to define the immunopathogenetic mechanisms responsible for human immunodeficiency syndromes. During the past year we have focused on the functional capacities of T and B cells from patients with common variable immunodeficiency (CVI). In studies of CVI patient T cells, we showed that while purified CD4 T cells proliferate normally in response to proliferation by PHA, staphylococcal enterotoxin B (SEB) and anti-CD2 antibodies, these stimuli induce significantly less IL-2 than normal CD4+ T cells. On the other hand, immobilized anti-CD3 antibody and this stimulus in combination with anti-CD28 antibody induced CVI T cells to produce normal amounts of IL-2. These studies thus demonstrate that the IL-2 production defect in CD4+ T cells is due to a specific signalling pathway abnormality. In a second series of studies, in this case focused on B cell function in CVI patients, we showed first that circulating B cells express normal amounts of sIgM+, but greatly reduced amounts of sIgG+ and sIgA+; this result implies that patients have an in vivo defect of isotype switch differentiation. In other studies, we showed that upon stimulation of purified patient B cells with anti-CD40 antibody plus IL-10, patient B cells expressed Cmu, Cgamma and Calpha mRNA; furthermore, stimulation of cells with anti-CD40 plus IL-10, followed by stimulation with activated T cells (which express the CD40 ligand), led to partial restoration of IgG and IgA synthesis. These studies thus indicate that CVI B cells can be partially restored to normal function in vitro, suggesting that the cells are not irreversibly blocked from isotype and terminal differentiation.
Showing the most recent 10 out of 11 publications
